SS Innovations International (NASDAQ: SSII), a developer of innovative surgical robotic technologies, has expanded the clinical footprint of its SSi Mantra surgical robotic system with the launch of a robotic cardiac surgery program at HCG Hospital, Mithakhali, in Ahmedabad, India. The program began with a robotic cardiac surgery LIMA take-down performed using the SSi Mantra 3.0 system. The procedure was led by Dr. Brajmohan Singh and proctored by Dr. Lalit Malik, with support from the SS Innovations team.
This development matters because it demonstrates the growing adoption of robotic-assisted cardiac surgery in India, a country with a high burden of cardiovascular disease and limited access to advanced surgical care. By enabling complex cardiac procedures through a robotic platform, SS Innovations is helping to address a critical unmet need and improve patient outcomes. The successful launch at HCG Hospital also validates the SSi Mantra system's capabilities in a new clinical domain, potentially opening doors to more cardiac programs across India and beyond.
The company reported 238 SSi Mantra systems installed as of September 8, up 42% from the end of 2025. The system is now installed across 12 countries, with recent expansion into Colombia, Sri Lanka and the Philippines. This rapid installation growth signals strong market acceptance and positions SS Innovations as a rising competitor in the global surgical robotics market, which has historically been dominated by a few large players. The expansion into new geographies also diversifies the company's revenue base and reduces dependence on any single market.
In a LinkedIn post, the company wrote, “We congratulate Dr. Brajmohan Sinh, Dr. Lalit Malik, and the entire team at HCG Hospital for this achievement, and thank them for their trust and commitment in advancing robotic cardiac surgery in the region.” The post can be found at https://ibn.fm/TTTdR. The company further stated, “At SS Innovations International, Inc. we remain committed to enabling hospitals and…” The full announcement is available at Read More>>.
SS Innovations is pursuing U.S. FDA review and European Union CE marking as it seeks to expand SSi Mantra into additional international markets. Regulatory clearances in these major markets would significantly enhance the company's credibility and accelerate adoption among hospitals in the U.S. and Europe. The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII.
The expansion of robotic cardiac surgery at HCG Hospital, combined with the company's global growth and regulatory ambitions, underscores the increasing role of robotics in transforming surgical care. As SS Innovations continues to penetrate new markets and clinical applications, it is well-positioned to capitalize on the shift toward minimally invasive, robot-assisted procedures worldwide.
